L-NBDNJ
L-NBDNJ, a glycomimetic, is an antivirulence agent. L-NBDNJ interferes with the expression of proteins regulating cytoskeleton assembly and organization of the host cell. L-NBDNJ has anti-inflammatory and anti-infective effects in models of cystic fibrosis (CF) lung disease infection.
For research use only. We do not sell to patients.
- CAS No.: 2159078-06-3
- Formula: C10H21NO4
- Molecular Weight:219.28
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| SH-SY5Y | IC50 |
62 μM
Compound: ent-1; L-NBDNJ
|
Inhibition of GCase in human SH-SY5Y cells using MUG-Gluc as fluorogenic substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of conduritol B epoxide by fluorescence based assay
Inhibition of GCase in human SH-SY5Y cells using MUG-Gluc as fluorogenic substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of conduritol B epoxide by fluorescence based assay
|
[PMID: 31075609] |
| SH-SY5Y | IC50 |
7.7 μM
Compound: ent-1; L-NBDNJ
|
Inhibition of NLGase in human SH-SY5Y cells using MUG-Gluc as fluorogenic substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of AMP-DNM by fluorescence based assay
Inhibition of NLGase in human SH-SY5Y cells using MUG-Gluc as fluorogenic substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of AMP-DNM by fluorescence based assay
|
[PMID: 31075609] |
L-NBDNJ, a glycomimetic, is an antivirulence agent. L-NBDNJ interferes with the expression of proteins regulating cytoskeleton assembly and organization of the host cell. L-NBDNJ has to interfere with the metabolic paths involved in cytoskeleton assembly and organization of the host cell, downregulate the main virulence factors of P. aeruginosa involved in the host response, and affect pathogen adhesion to human cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57Bl/6NCr mice infected by P. aeruginosa MDR-RP73[1]
-
Dosage:10 and 100 mg/kg
-
Administration:Oral gavage; daily; for 6 days (starting 24 h before infection)
-
Result:A significant and substantial decrease in bacteria recovered from the airways of mice observed[1].
Showed a moderate reduction of some chemokines and cytokines activated by infection[1].
Chemical Information
-
CAS No. 2159078-06-3
-
Molecular Weight 219.28
-
Formula C10H21NO4
-
SMILES
CCCCN1[C@@H](CO)[C@H](O)[C@@H](O)[C@H](O)C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
L-NBDNJ Related Classifications
HY-162496 Related Classifications
Powered by Bioz